鼻腔给药市场：依产品、剂量、应用、通路 - 2025-2030 年全球预测

2023年鼻腔给药市值为518.9亿美元，预计2024年将达到558.8亿美元，复合年增长率为8.17%，预计到2030年将达到899.3亿美元。

鼻腔药物传递和经鼻吸入型疫苗递送涉及透过鼻腔施用治疗剂并利用富含血管的鼻上皮来快速吸收。这种需求是因为它的非侵入性、改善的患者依从性，特别是效用在绕过胃肠道和初级代谢、提高蛋白质、胜胜肽和疫苗的生物有效性的有用性。应用范围广泛，包括过敏性鼻炎、偏头痛、骨质疏鬆症和疫苗输送，特别是 COVID-19 疫苗的最新进展。最终用途细分包括医院、诊所和居家医疗机构，越来越偏好自我管理治疗。关键的市场成长要素包括配方技术和输送设备的技术进步、积极的监管前景以及需要非侵入性输送系统的慢性疾病盛行率的增加。新的商机在于消费者对无针药物替代品不断增长的需求，以及对中枢神经系统疾病和大流行病预防的创新鼻製剂研发的大量投资。儘管有这些前景，挑战仍然存在，包括药物渗透性、黏膜清除以及鼻腔给药药物潜在的局部刺激。监管复杂性和高昂的开发成本进一步阻碍了市场的稳定发展。为了克服这些问题，有一些成熟的创新领域，包括黏合聚合物的增强、奈米载体系统，以及具有优化稳定性和生物有效性的控制释放特性的新型装置。生物技术公司和研究机构之间的联合倡议可以加速针对阿兹海默症、帕金森氏症和肠溶製剂的药物开发。鼻腔给药市场的特点是竞争激烈且创新，需要结合製药专业知识和尖端技术的策略联盟。随着公司在这一发展中领域的发展，将研发重点放在未满足的市场需求上并探索监管途径似乎可以解决现有的市场障碍，同时抓住新的机会。

市场动态：揭示快速发展的鼻腔给药市场的关键市场洞察

供需的动态交互作用正在改变鼻腔给药市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

• 市场驱动因素
  • 呼吸系统和神经系统疾病的盛行率上升
  • 供应链网络扩张与商业化
  • 非侵入性给药途径处方增加
• 市场限制因素
  • 与鼻腔给药相关的副作用
• 市场机会
  • 新兴经济体改善医疗基础设施和先进治疗的潜力
  • 鼻腔给药系统相关技术的进步
• 市场挑战
  • 开发问题，例如疫苗需要大剂量以及难以透过鼻腔途径给药

波特五力：驾驭鼻腔给药市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更具弹性的市场定位。

PESTLE分析：了解对鼻腔给药市场的外部影响

外部宏观环境因素在塑造鼻腔给药市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解鼻腔给药市场的竞争状况

鼻腔给药市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵鼻给药市场供应商的绩效评估

FPNV 定位矩阵是评估鼻腔给药市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製鼻腔给药市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，鼻腔给药市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 呼吸系统和神经系统疾病的盛行率增加
    • 供应链网络扩张与商业化
    • 非侵入性给药途径的处方数量不断增加
  • 抑制因素
    • 与鼻腔给药相关的副作用
  • 机会
    • 改善新兴经济体的医疗基础设施并提供先进的治疗方法
    • 鼻腔给药系统的技术进步
  • 任务
    • 疫苗需要大剂量、鼻内给药困难等发展挑战
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章鼻腔给药市场：副产品

• 供液装置
• 送粉装置
• 加压定量吸入器

第七章鼻腔给药市场（按剂量）

• 多剂量
• 单位剂量

第八章鼻腔给药市场：依应用分类

• 神经系统疾病
• 疼痛管理
• 呼吸系统疾病
• 疫苗接种

第九章鼻腔给药市场：依分销管道划分

• 医院药房
• 网路药房
• 零售药房

第十章北美及南美鼻腔给药市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十一章亚太地区鼻腔给药市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十二章 欧洲、中东和非洲鼻腔给药市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十三章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• 3M Company
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Baxter International, Inc.
• Becton, Dickinson, and Company
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Marina Biotech, Inc.
• Merck & Co., Inc.
• Neurelis Inc.
• Novartis AG
• OptiNose, Inc.
• Pfizer Inc.
• Teleflex Incorporated
• Teva Pharmaceutical Industries Ltd.

The Intranasal Drug & Vaccine Delivery Market was valued at USD 51.89 billion in 2023, expected to reach USD 55.88 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 89.93 billion by 2030.

The scope of intranasal drug and vaccine delivery involves administering therapeutics through the nasal cavity, leveraging the highly vascularized nasal epithelium for rapid absorption. Its necessity stems from the non-invasive nature, improved patient compliance, and particularly its utility in bypassing the gastrointestinal tract and first-pass metabolism, enhancing bioavailability of proteins, peptides, and vaccines. Applications are diverse, spanning allergic rhinitis, migraine, osteoporosis, and notably vaccine delivery with recent advancements in COVID-19 vaccines. End-use segmentation includes hospitals, clinics, and home care settings, with increasing preference for self-administered treatments. Key market growth factors involve technological advancements in formulation techniques and delivery devices, positive regulatory outlooks, and a growing prevalence of chronic diseases that demand non-invasive delivery systems. Emerging opportunities lie in the rising consumer demand for needle-free alternatives and significant investments in R&D for innovative nasal formulations that address central nervous system disorders and pandemic preparedness. Despite these prospects, challenges loom in the form of limited drug permeation, mucociliary clearance, and the nasally administered agent's potential local irritation. Regulatory complexities and high development costs further impede steady market progress. To overcome these, areas ripe for innovation include enhanced mucoadhesive polymers, nanocarrier systems, and novel devices with controlled release properties that optimize stability and bioavailability. Collaborative initiatives between biotech firms and research institutions can accelerate the development of drugs targeting Alzheimer's, Parkinson's, and enteric-coated formulations for improved targeting. The intranasal delivery market is characterized by a competitive yet innovative landscape, demanding strategic alliances to combine medicinal expertise with advanced technology. As businesses navigate this evolving sector, aligning R&D focus with market unmet needs and advancing regulatory pathways could seize emerging opportunities while addressing existing market barriers.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intranasal Drug & Vaccine Delivery Market

The Intranasal Drug & Vaccine Delivery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of respiratory and neurological diseases
  • Expansion of supply chain networks and commercialization
  • Rise in number of prescriptions for non-invasive drug delivery routes
• Market Restraints
  • Side effects associated with the use of nasal routes
• Market Opportunities
  • Improving healthcare infrastructure and advanced treatment availability in developing economies
  • Technological advancements related to nasal drug delivery systems
• Market Challenges
  • Development challenges such as requirements of large dose of vaccine and administration difficulties through the nasal route

Porter's Five Forces: A Strategic Tool for Navigating the Intranasal Drug & Vaccine Delivery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intranasal Drug & Vaccine Delivery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intranasal Drug & Vaccine Delivery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intranasal Drug & Vaccine Delivery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intranasal Drug & Vaccine Delivery Market

A detailed market share analysis in the Intranasal Drug & Vaccine Delivery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intranasal Drug & Vaccine Delivery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intranasal Drug & Vaccine Delivery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intranasal Drug & Vaccine Delivery Market

A strategic analysis of the Intranasal Drug & Vaccine Delivery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intranasal Drug & Vaccine Delivery Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AstraZeneca PLC, Bausch Health Companies Inc., Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Marina Biotech, Inc., Merck & Co., Inc., Neurelis Inc., Novartis AG, OptiNose, Inc., Pfizer Inc., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Intranasal Drug & Vaccine Delivery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Liquid Delivery Device, Powder Delivery Device, and Pressurized Metered Dose Inhaler.
• Based on Dosage, market is studied across Multi-Dose and Unit-Dose.
• Based on Application, market is studied across Neurological Disorders, Pain Management, Respiratory Disorders, and Vaccination.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of respiratory and neurological diseases
    • 5.1.1.2. Expansion of supply chain networks and commercialization
    • 5.1.1.3. Rise in number of prescriptions for non-invasive drug delivery routes
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with the use of nasal routes
  • 5.1.3. Opportunities
    • 5.1.3.1. Improving healthcare infrastructure and advanced treatment availability in developing economies
    • 5.1.3.2. Technological advancements related to nasal drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Development challenges such as requirements of large dose of vaccine and administration difficulties through the nasal route
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Intranasal Drug & Vaccine Delivery Market, by Product

• 6.1. Introduction
• 6.2. Liquid Delivery Device
• 6.3. Powder Delivery Device
• 6.4. Pressurized Metered Dose Inhaler

7. Intranasal Drug & Vaccine Delivery Market, by Dosage

• 7.1. Introduction
• 7.2. Multi-Dose
• 7.3. Unit-Dose

8. Intranasal Drug & Vaccine Delivery Market, by Application

• 8.1. Introduction
• 8.2. Neurological Disorders
• 8.3. Pain Management
• 8.4. Respiratory Disorders
• 8.5. Vaccination

9. Intranasal Drug & Vaccine Delivery Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Intranasal Drug & Vaccine Delivery Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Intranasal Drug & Vaccine Delivery Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3M Company
• 2. AstraZeneca PLC
• 3. Bausch Health Companies Inc.
• 4. Baxter International, Inc.
• 5. Becton, Dickinson, and Company
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Marina Biotech, Inc.
• 9. Merck & Co., Inc.
• 10. Neurelis Inc.
• 11. Novartis AG
• 12. OptiNose, Inc.
• 13. Pfizer Inc.
• 14. Teleflex Incorporated
• 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
• FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
• TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID DELIVERY DEVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER DELIVERY DEVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023